S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
The Next Big Crisis Is Here (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
The Next Big Crisis Is Here (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Dutch firm: US, allies near deal to limit chip tech to China
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
The Next Big Crisis Is Here (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
The Next Big Crisis Is Here (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Dutch firm: US, allies near deal to limit chip tech to China
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
The Next Big Crisis Is Here (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
The Next Big Crisis Is Here (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Dutch firm: US, allies near deal to limit chip tech to China
S&P 500   3,852.36
DOW   32,920.46
QQQ   296.26
Inflation Tips for Startups – Top 11
The Next Big Crisis Is Here (Ad)
Trustees picked by DeSantis may change progressive college
Qatar replaces Russian company in Lebanon gas exploration
The Next Big Crisis Is Here (Ad)
France must raise pension age to 64, prime minister says
Elon Musk's mysterious ways on display in Tesla tweet trial
The Next Big Crisis Is Here (Ad)
Biden, McCarthy to discuss debt limit in talks on Wednesday
Dutch firm: US, allies near deal to limit chip tech to China
NASDAQ:ATHE

Alterity Therapeutics - ATHE News Today

$3.91
+0.10 (+2.62%)
(As of 01/27/2023 12:00 AM ET)
Add
Compare
Today's Range
$3.80
$3.97
50-Day Range
$2.95
$4.29
52-Week Range
$2.90
$10.50
Volume
25,947 shs
Average Volume
22,031 shs
Market Capitalization
$15.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.00
Get Alterity Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ATHE and its competitors with MarketBeat's FREE daily newsletter.



ATHE Media Mentions By Week

ATHE Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ATHE
News Sentiment

0.62

0.72

Average
Medical
News Sentiment

ATHE News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ATHE Articles
This Week

3

0

ATHE Articles
Average Week

SourceHeadline
finance.yahoo.com logoAlterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in Italy for the Treatment of Individuals with Multiple System Atrophy
finance.yahoo.com - January 25 at 8:28 AM
finance.yahoo.com logoAlterity Therapeutics Launches ATH434 Phase 2 Clinical Trial in the United States for the Treatment of Individuals with Multiple System Atrophy
finance.yahoo.com - January 9 at 3:15 PM
msn.com logoAlterity Therapeutics to implement 1-for-10 reverse ADS split
msn.com - January 7 at 10:58 AM
finance.yahoo.com logoAlterity Therapeutics Announces 1-for-10 Reverse ADS Split (consolidation)
finance.yahoo.com - January 6 at 12:16 PM
finance.yahoo.com logoAlterity Therapeutics to Participate in the Sachs Associates 6th Annual Neuroscience Innovation Forum
finance.yahoo.com - January 3 at 12:42 PM
finance.yahoo.com logoAlterity Therapeutics Announces Presentation of Data from the bioMUSE Natural History Study at the American Autonomic Society Annual Meeting
finance.yahoo.com - November 7 at 3:14 PM
finance.yahoo.com logoAppendix 4C - Q1 FY23 Quarterly Cash Flow Report
finance.yahoo.com - November 5 at 5:45 AM
finance.yahoo.com logoAlterity Therapeutics Announces Presentation of MRI Data from the bioMUSE Natural History Study at the American Neurological Association Annual Meeting
finance.yahoo.com - October 26 at 11:50 AM
finance.yahoo.com logoAlterity Therapeutics Announces Presentation of Wearable Sensor Data from the bioMUSE Natural History Study at the International Congress of Parkinson's Disease and Movement Disorders
finance.yahoo.com - September 26 at 9:47 AM
marketwatch.com logoAlterity Therapeutics Gets FDA Approval for IND Application for ATH434
marketwatch.com - September 20 at 5:06 PM
nasdaq.com logoAlterity Gets FDA Nod To Conduct Phase 2 Trial Of ATH434 In Multiple System Atrophy
nasdaq.com - September 20 at 5:06 PM
finance.yahoo.com logoAlterity Therapeutics Receives U.S. FDA Approval for Investigational New Drug Application for ATH434 for the Treatment of Multiple System Atrophy
finance.yahoo.com - September 20 at 5:06 PM
finance.yahoo.com logoAlterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy in Europe
finance.yahoo.com - August 25 at 7:33 AM
finance.yahoo.com logoAlterity Therapeutics: Appendix 4C - Q4 FY22 Quarterly Cash Flow Report
finance.yahoo.com - July 22 at 11:02 AM
seekingalpha.com logoAlterity wins Italian nod to study lead asset in Parkinsonian disorder
seekingalpha.com - June 23 at 5:40 PM
finance.yahoo.com logoLife Sciences Investor Forum: Company Executives Present Live June 23rd
finance.yahoo.com - June 21 at 8:41 AM
finance.yahoo.com logoAlterity Therapeutics to Present at the VirtualInvestorConferences.com Life Sciences Investor Forum
finance.yahoo.com - June 20 at 7:39 AM
finance.yahoo.com logoAlterity Therapeutics Launches ATH434 Phase 2 Clinical Trial for the Treatment of Patients with Multiple System Atrophy
finance.yahoo.com - June 2 at 10:54 AM
seekingalpha.com logoAlterity gsts UK drug regulator nod for phase 2 study of ATH434 for multiple system atrophy
seekingalpha.com - April 27 at 10:34 AM
finance.yahoo.com logoAlterity Therapeutics Announces Regulatory Authorization to Proceed with ATH434 Phase 2 Clinical Trial in the United Kingdom
finance.yahoo.com - April 27 at 10:34 AM
finance.yahoo.com logoAlterity Therapeutics to Present at the 34th Annual Roth Conference
finance.yahoo.com - March 7 at 11:36 AM
nasdaq.com logoAlterity Therapeutics Limited American Depositary Shares (ATHE)
nasdaq.com - February 14 at 12:06 AM
finance.yahoo.com logoAlterity Therapeutics Highlights New Publications On ATH434 In Parkinson's Disease
finance.yahoo.com - January 28 at 6:39 PM
seekingalpha.com logoAlterity announces publication of animal study on lead asset
seekingalpha.com - January 28 at 8:05 AM
finance.yahoo.com logoAlterity Therapeutics Announces Publication Demonstrating that ATH434 is Neuroprotective in Animal Model of Parkinsonian Disorder in the Journal of Parkinson's Disease
finance.yahoo.com - January 28 at 8:05 AM
finance.yahoo.com logoAppendix 4C - Q2 FY22 Quarterly Cash Flow Report
finance.yahoo.com - January 27 at 8:39 AM
markets.businessinsider.com logoPre-market Movers: KAVL, ATHE, BLI, PSTV, CNSP…
markets.businessinsider.com - January 6 at 8:43 AM
seekingalpha.com logoAlterity Therapeutics wins U.S. patent related to neurological diseases
seekingalpha.com - January 6 at 8:43 AM
finance.yahoo.com logoAlterity Therapeutics Granted New US Patent for Compounds for Neurodegenerative Diseases Including Parkinson's and Alzheimer's
finance.yahoo.com - January 6 at 8:43 AM
finance.yahoo.com logoAlterity Therapeutics to Present at the H.C. Wainwright BIOCONNECT Virtual Conference
finance.yahoo.com - January 5 at 9:54 AM
finance.yahoo.com logoAlterity Therapeutics to Participate in Two Upcoming Investor Conferences
finance.yahoo.com - November 22 at 8:31 AM
finance.yahoo.com logoAlterity Therapeutics Announces Presentation of ATH434 at the American Autonomic Society Virtual Meeting 2021
finance.yahoo.com - November 9 at 9:51 AM
finance.yahoo.com logoAlterity Therapeutics Announces New Publications Providing Further Evidence of the Potential of ATH434 to Treat Neurodegenerative Diseases
finance.yahoo.com - November 4 at 8:46 AM
finance.yahoo.com logoAppendix 4C - Q1 FY22 Quarterly Cash Flow Report
finance.yahoo.com - October 29 at 9:00 AM
seekingalpha.com logoATHE, NMTR and PXLW among pre among gainers
seekingalpha.com - August 22 at 3:36 PM
msn.com logo99 Biggest Movers From Yesterday
msn.com - August 6 at 10:01 AM
marketwatch.com logoThinking about buying stock in Exela Technologies, Alterity Therapeutics, Farmmi, Micron Technology, or Under Armour?
marketwatch.com - August 5 at 8:18 AM
finance.yahoo.com logoAlterity Therapeutics Announces New US Patent to Expand its Portfolio of Compounds for Neurodegenerative Diseases including Alzheimer's and Parkinson's
finance.yahoo.com - August 4 at 9:44 AM
finance.yahoo.com logoAppendix 4C - Q4 FY21 Quarterly Cash Flow Report
finance.yahoo.com - July 30 at 1:23 PM
markets.businessinsider.com logoAlterity Therapeutics Says Treatment With ATH434 Neuroprotective And Improved Motor Function
markets.businessinsider.com - July 15 at 12:29 PM
markets.businessinsider.com logoPre-market Movers: ATHE, HUDI, VERB, SGOC, IMUX…
markets.businessinsider.com - July 15 at 7:29 AM
proactiveinvestors.com.au logoAlterity Therapeutics shares rise as its new US patent supports bid to find treatment for Alzheimer's and Parkinson's
proactiveinvestors.com.au - July 1 at 6:03 PM
finance.yahoo.com logoWant to Buy Alterity Therapeutics (ATHE) Stock? See This First.
finance.yahoo.com - July 1 at 6:03 PM
benzinga.com logoWhat's Sending Alterity Therapeutics Shares Higher?
benzinga.com - July 1 at 1:03 PM
finance.yahoo.com logoAlterity Therapeutics granted a new US patent targeting major neurodegenerative diseases including Alzheimer's and Parkinson's
finance.yahoo.com - July 1 at 8:02 AM
finance.yahoo.com logoAlterity Therapeutics Limited Received European Union Regulatory Guidance for ATH434 Phase 2 Clinical Trial
finance.yahoo.com - June 23 at 9:51 AM
finance.yahoo.com logoAlterity Therapeutics (ASX:ATH) Is In A Good Position To Deliver On Growth Plans
finance.yahoo.com - June 7 at 7:25 PM
finance.yahoo.com logoAlterity Therapeutics Limited Appendix 4C - Q3 FY21 Quarterly Cash Flow Report
finance.yahoo.com - April 29 at 8:47 AM
finance.yahoo.com logoAlterity's Stock Is Trading Higher As ATH434 Preserves Neurons, Motor Performance In Animal Model With Neurodegenerative Disorder
finance.yahoo.com - April 21 at 1:22 PM
msn.com logo24 Stocks Moving in Wednesday's Pre-Market Session
msn.com - April 21 at 8:21 AM
Get Alterity Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ATHE and its competitors with MarketBeat's FREE daily newsletter.

This page (NASDAQ:ATHE) was last updated on 1/29/2023 by MarketBeat.com Staff